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Cytokinins are important purine derivatives that act as hormones to control many processes in plants. Cytokinins such as
isopentenyladenine (IPA), kinetin and benzyladenine were very effective at inducing the granulocytic differentiation of human myeloid
leukemia HL-60 cells. The metabolism of cytokinins to their nucleotides was closely associated with cytokinin-induced differentiation and
growth inhibition. When the cells were incubated with [14C]-benzyladenine, radioactivity was significantly incorporated into RNA and
DNA. However, the radioactive nucleotides in RNA or DNA were adenine nucleotides, not benzyladenine nucleotides, suggesting that
cytokinins were not incorporated into RNA and DNA. The benzyladenine nucleotides were not stably released into the medium in intact
form. Cytokinins effectively induced a phosphorylated (active) form of mitogen-activated protein kinase (MAPK). MAPK activation was
necessary for cytokinin-induced differentiation, because PD98059, an inhibitor of MAPK kinase, suppressed the differentiation induced by
cytokinins. These results suggest that cytokinin nucleotides themselves play an important role in inducing the differentiation of HL-60
cells.
D 2003 Elsevier B.V. All rights reserved.Keywords: Cytokinin; Plant hormone; Nucleotide; Metabolism; Granulocytic differentiation; Mitogen-activated protein kinase; Leukemia cell1. Introduction
Acute myeloid leukemia (AML) cells do not undergo the
cell differentiation that normally leads to mature functional
blood cells. Instead, they are arrested at immature stages of
development, and genes important for myeloid differentia-
tion are often affected by chromosomal changes in AML.
The arrest of maturation in myeloid leukemia cells can
sometimes be reversed, based on the results of studies of
established cell lines and leukemia cells in primary culture.
The differentiation of leukemia cells can be induced by
retinoids, 1a,25-dihydroxyvitamin D3(VD3), cytokines and0167-4889/$ - see front matter D 2003 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbamcr.2003.08.004
Abbreviations: AML, acute myeloid leukemia; IPA, isopentenylade-
nine; Ado, adenosine; dAdo, deoxyadenosine; NBT, nitroblue tetrazolium;
ATRA, all-trans retinoic acid; VD3, 1a,25-dihydroxyvitamin D3; PBS,
phosphate-buffered saline; tRNA, transfer RNA; MAPK, mitogen-activated
protein kinase; CDK, cyclin-dependent kinase
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pathways that mediate maturation in malignant cells by
bypassing genetic defects, thus reversing the malignant
phenotype.
Cytokinins are important purine derivatives that act as
hormones to control many processes in plants [5]. Cyto-
kinins were discovered as factors that promote cell divi-
sion in tobacco tissue cultures [6] and have been shown to
regulate several additional developmental events, such as
de novo bud formation, release of buds from apical
dominance, leaf expansion, delay of senescence, promo-
tion of seed germination and chloroplast formation [7].
Naturally occurring cytokinins are mainly adenine deriva-
tives such as isopentenyladenine (IPA) and trans-zeatin,
while synthetic cytokinins also include several adenine
analogs, such as kinetin and 6-benzyladenine [8]. Our
recent study showed that cytokinins effectively inhibit
the proliferation and induce the granulocytic differentiation
of human myeloid leukemia HL-60 cells [9]. 5V-Amino-2V-
deoxyadenosine (dAdo), an inhibitor of adenosine (Ado)
Y. Ishii et al. / Biochimica et Biophysica Acta 1643 (2003) 11–2412kinase [10], counteracts the effects of cytokinins on the
growth and differentiation of these cells. On the other
hand, Ado receptor A1 and A2 inhibitors hardly affected
the actions of cytokinins on HL-60 cells. These findings
suggest that the mechanism of action of cytokinins is
closely related to a metabolic process that requires phos-
phorylation by Ado kinase or its related enzymes [9]. The
causal connection between Ado metabolism and the mech-
anism of action of cytokinin-induced differentiation
remains to be elucidated. In this paper, we investigated
the intracellular uptake and metabolism of cytokinin in
HL-60 cells, and found that nucleotide formation is
closely associated with the mechanism of cytokinin-in-
duced differentiation.2. Materials and methods
2.1. Materials
All of the cytokinins and other adenine analogs, RPMI
1640 medium, nitroblue tetrazolium (NBT), all-trans
retinoic acid (ATRA), 1,3-diphenylurea, 1-phenyl-3-
(1,2,3-thiadiazol-5-yl)-urea (thidiazuron), and N-(2-
chloro-4-pyridyl)-NV-phenylurea (4-CPPU) were purchased
from Sigma Chemical Co. (St. Louis, MO), while VD3
and dimethyl sulfoxide were purchased from Wako Chem-
icals (Osaka, Japan). [8-14C]-Benzyladenine (1961 MBq/
mmol) was obtained from Moravek Biochemicals, Inc.
(Brea, CA).
2.2. Cell and cell culture
The HL-60 cell line, derived from an AML patient [11],
U937 monoblastic leukemia cells and K562 erythroleuke-
mia cells were maintained in RPMI 1640 medium supple-
mented with 10% fetal bovine serum and 80 Ag/ml
gentamicin at 37 jC in a humidified atmosphere of 5%
CO2 in air.
2.3. Assay of cell growth and properties of differentiated
cells
Suspensions of cells (0.5 105 cells/ml) in 2 ml of culture
medium were incubated with or without the test compounds
in multidishes (Costar, Cambridge, MA). Cell numbers were
counted in a Model ZM Coulter Counter (Coulter Electron-
ics, Luton, UK). Superoxide-generating oxidase was deter-
mined by the ability of the cells to reduce NBT upon
exposure to 12-O-tetradecanoyl phorbol-13-acetate [12].
Cells were incubated in 1 ml of RPMI 1640 medium
containing NBT (1 g/ml) and 12-O-tetradecanoyl phorbol-
13-acetate (100 ng/ml) at 37 jC for 50 min. The reaction was
stopped by adding 5 M HCl (1 M, final concentration). The
suspension was kept at room temperature for 20 min and
then centrifuged. Formazan deposits were solubilized indimethyl sulfoxide, and the absorption of the formazan
solution at 560 nm/107 cells was measured in a spectropho-
tometer. Morphological changes were examined in cell
smears stained with May-Gru¨nwald-Giemsa solution. Ery-
throid differentiation was measured by scoring cells stained
with benzidine as hemoglobin-producers, as described else-
where [13].
2.4. Uptake of benzyladenine and assay of its metabolites
Cells were preincubated at 37 or 4 jC for 10 min, and 37
kBq of [14C]-benzyladenine was added to the cell suspen-
sion (2 107 cells/10 ml). Incubation was carried out at 37
or 4 jC for various durations up to 180 min, and stopped by
adding 5 volumes of cold phosphate-buffered saline (PBS).
The cells were then washed three times with cold PBS and
homogenized in 1-ml cold 10% (w/v) perchloric acid. After
standing for 20 min, the sample was centrifuged and the
supernatant was set aside as the acid-soluble fraction. The
perchloric acid-insoluble pellet was washed twice in 1-ml
5% perchloric acid and once in 1 ml of ethanol. RNA was
extracted from the acid-insoluble pellet by hydrolysis for 20
h at 37 jC in 0.5 ml of 1 M KOH. After alkaline hydrolysis,
the sample was cooled and neutralized with 0.1 ml of 6 M
HCl–5% perchloric acid. The resultant supernatant and
pellet were considered RNA and DNA/protein fractions,
respectively. Aliquots were then taken for the assay of
radioactivity. Radioactivity was determined by liquid scin-
tillation counting. To further analyze the labeled RNA,
DNA and protein, we isolated them by the procedure of
Chomczynski [14] using Isogen, a reagent that contains
phenol and guanidine thiocyanate (Nippon Gene, Toyama,
Japan).
Ascending chromatography on Silica Gel 60F254
(Merck, Darmstadt, Germany) was used to separate benzy-
ladenine and its metabolites. The cell suspension (0.4 ml)
was mixed with tetrahydrofuran (1.2 ml). Authentic com-
pounds were then added to the supernatant and an aliquot
(50 Al) was spotted on a chromatographic sheet, which was
developed in a solvent system of chloroform/methanol/water
(80/20/1, v/v/v) or n-butanol/water (86:14, v/v). The zones
corresponding to authentic compounds were evaluated by
autoradiography with a Fuji Bio-Image Analyzer BAS2000
(Fuji Film Co, Ltd., Tokyo, Japan). Digestion of RNA and
DNA into nucleosides was accomplished usingMicrococcus
nuclease and alkaline phosphatase. DNA or RNA (10 Ag)
was incubated with 50 U ofMicrococcus nuclease in 50 Al of
reaction buffer (Takara Co, Ltd., Tokyo) at 37 jC for 60 min,
and then 5 Al of 10 buffer and 10 U of calf intestine
alkaline phosphatase (Takara) were added and incubation
was continued for an additional 60 min. After incubation, the
digested sample was mixed with 0.15 ml of tetrahydrofuran
and used to identify radioactive benzyladenine in RNA and
DNA. Nucleotide monophosphates in the acid-soluble frac-
tion were digested to nucleosides by this phosphatase
treatment.
Table 1
Effects of adenine analogs on the growth of HL-60 and K562 cells
Analog Growth inhibition (IC50, AM)
HL-60 K562
Adenine 283F 22 643F 32
Kinetin 52.3F 4.3 162F 11
Isopentenyladenine 51.2F 5.5 197F 16
Benzyladenine 75.5F 6.9 121F13
2,6-Diaminopurine 65.9F 6.1 201F19
Cells were cultured with various concentrations of the analogs for 4 days.
MeansF S.D. of three separate experiments are shown. The IC50 is the
concentration of compound required for a 50% inhibition of cell growth.
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A cell suspension (0.4 ml) wasmixed with tetrahydrofuran
(1.2 ml). The supernatant fluids were dried up, dissolved inFig. 1. Effects of cytokinins on growth and differentiation of leukemia cells. (A) Eff
cells. HL-60 and K562 cells were cultured with various concentrations of adenine a
separate experiments. (n) adenine; (.) kinetin; (E) IPA; (o) benzyladenine; (5
reduction of HL-60 cells. Cells were cultured with various concentrations of 1,6-dip
as the mean of three separate experiments.distilled water and put on a column (Dowex 1-X 8, 200-400
mesh, formate form). Elution was performed with distilled
water and then 0.1 M formic acid to remove benzyladenine,
and the nucleosides and monophosphates were removed by 1
M and 4 M formic acid, respectively. The nucleotide diphos-
phates, triphosphates and others were removed by 0.2 M
ammonium formate–4 M formic acid, 0.8 M ammonium
formate–4 M formic acid and 88% formic acid [15].
2.6. Assay of mitogen-activated protein kinase (MAPK)
activity
MAPK activity was measured by the phosphorylation of
Elk-1, one of the in vivo targets of MAPK. The kinase assay
was performed using a p44/42 MAP Kinase Assay Kit (New
England Biolabs, Beverly, MA, USA) according to the
manufacturer’s instructions.ects of adenine analogs on the differentiation of HL-60 (left) and K562 (right)
nalogs for 5 and 4 days, respectively. Results are given as the mean of three
) 2,6-dimethyladenine. (B) Effects of urea-cytokinins on growth and NBT
henylurea (E), thidiazuron (n) or 4-CPPU (.) for 5 days. Results are given
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3.1. Effects of various adenine analogs on the growth and
differentiation of HL-60 and K562 cells
Human myeloid leukemia HL-60 cells were cultured with
various concentrations of the analogs for 5 days, and the
concentrations of the analogs that inhibited viable cell
numbers by 50% (IC50) were calculated (Table 1). IPA,
kinetin and 6-benzyladenine, which are well-known cytoki-
nins in plants [9], were more potent than purine or other
adenine analogs at inhibiting cell growth. NBT-reducing
activity, a typical marker of myelomonocytic differentiation,
was significantly induced by several adenine analogs. IPA,
kinetin and benzyladenine were more potent than the otherFig. 2. Enhancing effect of Ado on growth inhibition and NBT reduction in H
concentrations of benzyladenine in the presence of 0 (.), 37 (n), 74 (E) and 111
(x) AM dAdo (C, D) for 5 days. Results are given as the mean of three separateanalogs at inducing NBT reduction (Fig. 1A). Similar results
were obtained in other myelomonocytic leukemia cell lines,
such as NB4, U937 and THP-1. IPA and kinetin induced the
morphologic differentiation of HL-60 cells into granulocytes
without apparent apoptosis after 6 days. The cytokinin-
induced differentiation of HL-60 cells was confirmed by
examining other differentiation-associated properties, such
as lysozyme activity and CD11b expression.
The human leukemia cell line K562 was originally
established from pleural effusion of a patient with chronic
myelogenous leukemia in terminal blast crisis [16]. Ery-
throid differentiation of this cell line has been shown with
various inducers. After incubation for 4 days, several
adenine analogs were found to inhibit the growth of
K562 cells (Table 1). Benzidine positivity is a marker ofL-60 cells treated with benzyladenine. Cells were cultured with various
(x) AM Ado (A, B), and in the presence of 0 (.), 74 (n), 148 (E) and 222
experiments.
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tent roughly paralleled the increase in the percentage of
benzidine-positive cells [13]. Among the analogs exam-
ined, adenine was the most potent at inducing the ery-
throid differentiation of K562 cells, whereas benzyladenine
and 2,6-dimethyladenine were ineffective at inducing he-
moglobin-positive cells (Fig. 1A). These results indicate
that the structure–activity relationships of adenine analogs
for inducing the erythrodifferentiation of K562 cells are
clearly different from those for myelomonocytic leukemia
cells.
Next we examined the differentiation-inducing effects of
non-adenine cytokinins on HL-60 cells. Although 1,3-diphe-
nylurea did not essentially affect the growth and differenti-Fig. 3. Intracellular uptake of benzyladenine and synthesis of its nucleotides in HL
presence of 0.1 mM Ado or 0.2 mM dAdo for 3 h. After incubation, cells were wa
chromatographic analysis of benzyladenine metabolites. (C) Kinetic analysis of nu
durations at 37 jC (.) or 4 jC (n), and the cell extracts with tetrahydrofuran
benzyladenosine; BA-N, benzyladenine nucleotides.ation of the cells, thidiazuron and 4-CPPU inhibited cell
growth and induced NBT reduction in a concentration-
dependent manner (Fig. 1B). These results indicate that
some urea-cytokinins are also effective at inducing differen-
tiation of human myeloid leukemia cells.
3.2. Effects of Ado on the growth and differentiation of
leukemia cells in the presence of adenine analogs
The action of cytokinins in HL-60 cells may be at least
partly associated with Ado metabolism, and 5V-amino-dAdo,
an inhibitor of Ado kinase [11], reduced the growth inhibi-
tion and differentiation induced by cytokinins [9]. These
results indicate that the differentiation-inducing effects of-60 cells. (A) Cells were cultured with 37 kBq of [14C]-benzyladenine in the
shed twice with cold PBS and the radioactivity was counted. (B) Thin layer
cleotide synthesis. Cells were cultured with [14C]-benzyladenine for various
were subjected to thin layer chromatography. BA, benzyladenine; BA-R,
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processes that require phosphorylation by Ado kinase or
related enzymes. 5V-Amino-dAdo also affected the adenine-
induced differentiation of K562 cells, suggesting that the
differentiation-inducing effect of adenine also requires its
phosphorylation in K562 cells.
Although Ado alone was less effective at inducing the
differentiation of HL-60 cells, it greatly enhanced the
growth inhibition and differentiation induced by cytokininsFig. 4. Effects of Ado and 5V-amino-dAdo on differentiation and nucleotide s
benzyladenine in the presence of 0 (open bar) or 37 (closed bar) AM Ado (A), or i
days. Results are given as the meanF S.D. of three separate experiments. (C)
incubated with 37 kBq of [14C]-benzyladenine in the presence or absence of
benzyladenine nucleotides. Cells were incubated with 37 kBq of [14C]-benzylade
results were obtained three times and typical results are shown.(Fig. 2). Cytokinin-induced NBT reduction was not essen-
tially affected by dAdo, adenine or isopentenyladenosine,
suggesting that the enhancing effect of Ado is rather
specific. Similar results were obtained when other human
myelomonocytic leukemia cell lines such as NB-4, HT-93,
U937, THP-1 and KOCL48 cells were cultured with cyto-
kinins and/or Ado derivatives. Ado also augmented the
differentiation of erythroleukemia K562 cells induced by
adenine or IPA.ynthesis in benzyladenine-treated HL-60 cells. Cells were cultured with
n the presence of 0 (open bar) or 1 (closed bar) AM 5V-amino-dAdo (B) for 5
Effect of Ado on the synthesis of benzyladenine nucleotides. Cells were
0.1 mM Ado for 3 h. (D) Effect of 5V-amino-dAdo on the synthesis of
nine in the presence or absence of 1 AM 5V-amino-dAdo for 1 day. Similar
Fig. 5. Incorporation of benzyladenine into the acid-soluble fraction, RNA and DNA/protein of HL-60 cells. (A) Kinetic analysis of incorporation. Results are
given as the mean of three separate experiments. (B) Detection of benzyladenine nucleotides in HL-60 cells. Cells were incubated with [14C]-benzyladenine for
the indicated durations, and then extracted with tetrahydrofuran. Nucleotides were separated from nucleobases and nucleosides by thin layer chromatography
(n-butanol/water, 86:14). The spots corresponding to nucleotides were scraped off and extracted with 2 M formic acid. After formic acid was removed by
lyophilization, the nucleotides were treated with alkaline phosphatase. An aliquot was spotted on a chromatographic sheet, which was developed in a solvent
system of chloroform/methanol/water (80:20:1). BA, benzyladenine; BA-R, benzyladenosine; BA-N, benzyladenine nucleotides. (C) Chromatographic
separation of benzyladenine nucleotides. The labeling interval was 24 h. The total tetrahydrofuran-extracted materials were put on a Dowex-1 column. The
following eluents were used in succession: (1) water, (2) 0.1 M formic acid, (3) 1 M formic acid, (4) 4 M formic acid, (5) 4 M formic acid–0.2 M ammonium
formate, (6) 4 M formic acid–0.4 M ammonium formate, (7) 4 M formic acid–0.8 M ammonium formate, and (8) 88% formic acid. Arrows indicate when the
eluents were changed. Arrowheads indicate when the reference materials were eluted.
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Leukemia cells were treated with [14C]-benzyladenine at
37 or 4 jC for various lengths of time in the presence or
absence of 0.1 mM Ado. Treatment with Ado enhanced the
intracellular uptake of benzyladenine in HL-60 and U937
cells, while treatment with dAdo did not (Fig. 3A). At 37 jC,
the uptake of benzyladenine by leukemia cells rapidly
increased and a steady increase was observed with incuba-
tion for up to 3 h: most of the incorporated benzyladenine
was rapidly converted to nucleotides (Fig. 3B). At 4 jC, the
incorporation of benzyladenine into nucleotides was scarcely
Y. Ishii et al. / Biochimica et B18Fig. 6. Incorporation of [14C]-benzyladenine into RNA and DNA. (A) Cells were
absence (open bar) of 0.1 mM Ado. RNA, DNA and protein were isolated by the
protein were determined. Results are given as the mean of three separate experim
HL-60 cells with or without 0.1 mM Ado for 12 h. Staining with ethidium bromide
was treated with (+) or without ( ) nuclease and phosphatase. An aliquot was app
chloroform/methanol/water (80:20:1). (E) Release of labeled compounds from the
then washed three times with PBS. The cells were further incubated in fresh medi
were obtained three times and typical results are shown. BA, benzyladenine; BAobserved in either Ado-treated or untreated leukemia cells
(Fig. 3C).
HL-60 cells were treated with various concentrations of
benzyladenine in the presence of Ado or dAdo (Figs. 2 and
4A). Growth inhibition and NBT reduction were synergisti-
cally induced in HL-60 cells by benzyladenine and Ado, but
not by benzyladenine and dAdo. Similar results were
obtained in U937 monoblastic leukemia cells. On the other
hand, 5V-amino-dAdo counteracted the effects of benzylade-
nine on the growth and differentiation of HL-60 cells (Fig.
4B). The incorporation of labeled benzyladenine into nucleo-
tides was increased and decreased by Ado and 5V-amino-incubated with [14C]-benzyladenine for 12 h in the presence (closed bar) or
method of Chomczynski [14]. Radioactivities in purified RNA, DNA and
ents. (B and C) Electrophoretic pattern of RNA from benzyladenine-treated
(B) and radioautography (C). (D) Digestion of labeled DNA. Labeled DNA
lied to a chromatographic sheet, which was developed in a solvent system of
cells. Cells were incubated with 37 kBq of [14C]-benzyladenine for 12 h and
um without [14C]-benzyladenine for the indicated durations. Similar results
-R, benzyladenosine; BA-N, benzyladenine nucleotides.
Table 2
Effects of adenine analogs and some inhibitors of signal transduction on
IPA-induced differentiation
Compound Combined effect
with IPA
Adenosine analog
Adenosine Stimulative (++)
Deoxyadenosine No effect
2,5-Dideoxyadenosine Inhibitory ( )
Adenylate cyclase inhibitor
SQ2256 No effect
2,5-Dideoxyadenosine Inhibitory ( )
Protein kinase A inhibitor
K5720 No effect
Rp-8-Cl-cAMPS No effect
Protein kinase A activator
8Cl-cAMP Stimulative (+)
ATP, AMP Additive
8-CPT-cAMP Inhibitory ( )
8-CPT-cGMP No effect
P2 receptor antagonist
PPNDS, MRS2179 No effect
Adenosine receptor antagonist
DPCPX, DMPX, MRS1191 No effect
Phospholipase C inhibitor
U73122 No effect
HL-60 cells were treated with various concentrations of drugs in the presence
or absence of IPA for 5 days. All compounds were obtained from Sigma
Chemicals. Differentiation was assayed in terms of NBT-reducing activity
and morphological changes. The interaction of the two compounds was
quantified by determining the combination index (CI) according to the classic
isobogram [45,46]. ++, CI < 0.5; +, 0.5 <CI < 0.9;  , CI>1.5;  ,
1.2 <CI < 1.5.
Y. Ishii et al. / Biochimica et BiophydAdo, respectively (Fig. 4C and D). These results are
consistent with the effects of Ado or 5V-amino-dAdo on
growth inhibition and differentiation.
The incorporation of [14C]-benzyladenine into the acid-
soluble fraction, RNA and DNA/protein was investigated
(Fig. 5A). Most of the radioactivity incorporated after 3
h was in the acid-soluble fraction in both Ado-treated and
untreated HL-60 cells. Its incorporation into RNA and DNA
increased with the duration of incubation (Fig. 5A). The
acid-soluble extracts of cells incubated with benzyladenine
for 3 h were subjected to thin layer chromatography (Fig.
4C). The parental compound benzyladenine and benzylade-
nine nucleotides were mainly detected in both Ado-treated
and untreated HL-60 cells, while benzyladenosine was
scarcely detected. It is possible that the radioactive com-
pounds were converted to adenine and adenine nucleotides
by the intracellular elimination of a benzyl group. Therefore,
we separated benzyladenine and its metabolites from ade-
nine and its metabolites, and found that most of the
radioactivity was in benzyladenine and its nucleotides,
indicating that conversion to adenine, Ado and its nucleo-
tides scarcely occurred in cells during incubation for several
hours, but this conversion to adenine and its metabolites
gradually increased thereafter (Fig. 5B). Most of the nucleo-
tides were converted to nucleosides by treatment with
phosphatase, suggesting that the nucleotides were mainly
benzyladenosine monophosphate. We next analyzed the
labeled nucleotides using a Dowex-1 column and found
that the monophosphate was predominant in HL-60 cells
(Fig. 5C).
3.4. Identification of the labels in DNA and RNA
To eliminate the possibility that radioactive benzylade-
nine or its nucleotides might be contaminating RNA and
DNA/protein fractions, we isolated RNA, DNA and protein
by extraction using phenol–guanidium isothiocyanate
reagent [14]. The incorporation of radioactivity into puri-
fied RNA and DNA was confirmed (Fig. 6A) and the
results were consistent with those in Fig. 5A. The labeled
RNA was electrophoresed on agarose gel and transferred to
a nitrocellulose membrane. The radioactivity was deter-
mined and the results indicate that the radioactivity was
uniformly distributed in the RNA fraction, suggesting the
nonselective incorporation of radioactive nucleotides into
all of the RNA species in both Ado-treated and untreated
HL-60 cells (Fig. 6B and C). However, most of the
radioactive nucleotides in RNA and DNA were adenine
nucleotides, not benzyladenine nucleotides (Fig. 6D). These
results indicate that modification of RNA and DNA by
benzyladenine does not occur during the cytokinin-induced
differentiation of HL-60 cells. Similar results were obtained
when the cells were incubated for 3 or 12 h (data not
shown), suggesting that the elimination of a benzyl group
from radioactive nucleotides occurs before their incorpora-
tion into RNA/DNA.3.5. Release of benzyladenine nucleotides into the medium
The conversion of benzyladenine to nucleotides gradually
increased with incubation up to 20 h, while the conversion of
benzyladenine nucleotides to adenine nucleotides scarcely
occurred during incubation for 36 h. Thereafter, conversion
slightly increased and adenine nucleotides accounted for
about 15% of the total labeled nucleotides (Fig. 5B). HL-
60 cells were incubated with labeled benzyladenine for 12 h,
and then washed and reincubated without the label for 24 h.
The percentage of labeled nucleotides in cells decreased
during incubation, while the percentage of labeled com-
pounds in the medium significantly increased. About 90%
of the labeled benzyladenine nucleotides were found in cells
after 6 h of incubation (Fig. 6E), suggesting that the
benzyladenine nucleotides were stably retained in cells for
several hours even when labeled benzyladenine was re-
moved from the culture medium. The labeled compounds
released into the medium were mainly benzyladenosine and
benzyladenine, indicating that no benzyladenine nucleotides
were stably released into the medium.
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signal transduction on IPA-induced differentiation
Some adenine analogs such as cAMP and ATP have been
reported to induce some differentiation-associated pheno-
types in HL-60 cells [17,18]. Therefore, we examined the
effects of several adenine analogs on differentiation in the
presence or absence of IPA. 8-Cl-cAMP moderately, while
ATP slightly, induced NBT-reducing activity while neither
compound effectively induced morphological changes, as
previously reported [17,18]. The other compounds alone did
not induce NBT reduction by HL-60 cells. 8-Cl-cAMP and
IPA more than additively induced NBT reduction, while the
effects of IPA and either ATP or AMP were merely additive
(Table 2). 8-CPT-cAMP and 2V,5V-dideoxyAdo significantly
inhibited IPA-induced NBT reduction, while the other com-
pounds did not significantly affect the NBT reduction
induced by IPA. These results suggest that IPA-induced
differentiation is independent of signal transduction mediat-
Y. Ishii et al. / Biochimica et B20Fig. 7. Induction of MAPK activity in HL-60 cells by IPA or ATRA. Cells were tre
0.15 mM IPA in the absence and presence (+) of 0.5 AM PD98059 for 24 h (B).
PD98059 on growth inhibition and NBT-reducing activity of HL-60 cells induced
Values are meanF S.D. of four separate experiments.ed by cAMP and/or protein kinase A, and the inhibitory
effects of 8-CPT-cAMP and 2V,5V-dideoxyAdo are due to
different mechanisms.
3.7. MAPK activation by cytokinins
Although IPA is reported as a relatively nonspecific
protein kinase inhibitor [19,20], it may affect a protein
kinase(s) in a more specific manner. We examined effect of
IPA on activities of various protein kinases including cAMP-
activated, Src, EGF receptor, Flt-1, Ca/calmodulin-depen-
dent and protein kinase C. IPA and its nucleotide-mono-
phosphate did not essentially affect their activities (data not
shown). Next we examined the effects on MAPK activity,
since ATRA activated MAPK in HL-60 cells before inducing
granulocytic differentiation and growth arrest [21]. IPA
significantly increased MAPK activity by 2 h, and this
enhancement persisted for 24 h (Fig. 7). The enhancement
induced by IPA was more prominent than that induced byated with various concentrations of IPA for 3 h (A). Cells were treated with
Cells were treated with 0.15 mM IPA or 400 nM ATRA (C). (D) Effect of
by IPA for 4 days. (n) PD98059 alone, (o) PD98059 plus 0.1 mM IPA.
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pretreatment with PD98059 (Fig. 7B). This inhibitor also
suppressed the NBT reduction induced by IPA (Fig. 7D). The
urea-cytokinins also induced MAPK activity in HL-60 cells
before inducing differentiation (data not shown). These
results suggest that MAPK activation is required for cytoki-
nin-induced differentiation.
3.8. Commitment to differentiation and growth inhibition by
cytokinins
To determine whether cytokinin-induced differentiation
was reversible, we examined the effect of pulse treatment
with differentiation inducers on the differentiation of HL-60
cells. The cells were incubated with IPA for various lengths
of time, washed with fresh medium, and incubated in
medium without IPA. On day 6, NBT-reducing activities
and cell numbers were measured. When the cells wereFig. 8. One-day treatment with IPA, but not with ATRA or VD3, induced
commitment to differentiation in HL-60 cells. HL-60 cells were cultured
with 0.1 mM IPA, 400 nM ATRA or 24 nM VD3 for 1 day. Closed bar: the
cells were then washed with fresh medium and reincubated without the
inducers for 5 days. Open bar: the cells were continuously treated with 0.1
mM IPA, 400 nM ATRA or 24 nM VD3 for 6 days. Results are given as the
meanF S.D. of three separate experiments.incubated with IPA for 1 day and then cultured in the absence
of the drug for 5 days, a significant induction of NBT-
reducing activity and a growth-inhibitory effect were ob-
served (Fig. 8). This 1-day treatment with IPAwas similar to
continuous treatment with regard to commitment to differ-
entiation and growth inhibition in HL-60 cells, indicating
that the effect of IPA on the induction of differentiation was
irreversible. On the other hand, treatment with ATRA or
VD3 for 1 day was not sufficient to induce the differentiation
of HL-60 cells (Fig. 8), suggesting that continuous exposure
to these inducers is required to induce the differentiation of
HL-60 cells.4. Discussion
Human leukemia cells can be induced to differentiate by
several adenine derivatives. With respect to growth inhibi-
tion and differentiation induction, the structure–activity
relationships of adenine derivatives toward HL-60 cells are
similar to those toward other myelomonocytic leukemia cells
[9]. However, adenine was the most potent at inducing the
erythrodifferentiation of K562 cells, but not the differentia-
tion of myelomonocytic leukemia cells, suggesting that the
mechanism of differentiation induced by adenine analogs is
different from that in myelomonocytic leukemia cells.
Among the adenine derivatives, the differentiation-inducing
activities of myelomonocytic leukemia cells are closely
associated with their redifferentiation-inducing activities in
plants [9]. Although the effects of cytokinins on plant
development are well known, the mechanism of cytokinin
action is still not understood. In plants, cytokinin-binding
proteins and cytokinin receptors have been isolated and
shown to be involved in the cytokinin-signaling pathway
[22–25]. However, this signaling pathway seems to be
unlikely in human leukemia cells. The intracellular uptake
of cytokinin was greatly enhanced by Ado and this increased
uptake is closely correlated with the induction of cytokinin
responses in leukemia cells. The growth inhibition and
differentiation of cells induced by cytokinins may require
nucleotide synthesis of cytokinins. 5V-Amino-dAdo inhibits
the cytokinin-induced differentiation of leukemia cells and
also inhibits the uptake and conversion of cytokinin to
nucleotides. These results suggest that cytokinin action in
human leukemia cells is closely associated with nucleotide
synthesis and is not the same as that in plant cells.
Ado greatly and specifically stimulated the cytokinin-
induced differentiation of myelomonocytic leukemia cells.
Furthermore, Ado significantly enhanced the intracellular
uptake of cytokinin in HL-60 and U937 cells. These results
suggest that the differentiation-enhancing effect of Ado is
due to the increased uptake of cytokinin by Ado. Adenine
and purine derivatives are transported across the plasma
membrane by high-affinity transporters [26]. This uptake is
energy-dependent and occurs against a concentration gradi-
ent. When leukemia cells were treated with Ado, their ATP
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a maximal level (data not shown). However, the intracellular
uptake of cytokinin and the cytokinin-induced differentiation
of HL-60 cells were not significantly affected by glucose
(data not shown), suggesting that an increased ATP level
does not simply activate purine transporters and increase the
intracellular uptake of cytokinins. Although Ado greatly
enhanced the intracellular uptake of benzyladenine, Ado
did not essentially affect the ratio of benzyladenine to its
metabolites (nucleotides, RNA and DNA+protein), suggest-
ing that Ado did not qualitatively affect the metabolism of
benzyladenine in HL-60 cells.
More than 30% of [14C]-benzyladenine was incorporated
into RNA, DNA and protein fractions after incubation for 24
h. Thereafter, the incorporation into RNA increased even
when the labeled compound was removed from the culture.
Certain cytokinin derivatives have been shown to be incor-
porated into some transfer RNA (tRNA) and other RNA
molecules in plants [27–31]. The modification of tRNA is
common in eukaryotic and bacterial tRNAs [32–34] al-
though the function of this modification of tRNA in mam-
malian cells is unknown. HL-60 variants that are deficient in
the purine salvage enzyme hypoxanthine phosphoribosyl-
transferase can be induced to differentiate with purine anti-
metabolites without metabolic activation [35]. Moreover, the
tRNA wobble base queuine maintains the proliferative and
pluripotent potential of cells in the presence of the differen-
tiating agent 6-thioguanine [36]. However, the differentia-
tion induced by cytokinins in parental HL-60 cells required
the metabolic activation of cytokinins. The incorporation of
benzyladenine was not restricted to tRNA. Moreover, the
labels incorporated into RNA were adenine nucleotides, not
benzyladenine nucleotides. These results suggest that the
differentiation-inducing effects of cytokinins are not likely
due to the modification of tRNA by cytokinin.
Since labeled benzyladenine contains a radioactive car-
bon in the adenine structure, it is possible that the radioactive
compounds expel a benzyl group and turn into adenine
compounds. In HL-60 cells, the conversion of benzyladenine
to adenine was minimal, indicating that the labeled com-
pounds are fairly stable. However, the labels in RNA and
DNA were adenine nucleotides, not benzyladenine nucleo-
tides, indicating that the converted adenine nucleotides were
incorporated into DNA and RNA and gradually accumulated
in the nucleic acids. Methylation at adenine residues of DNA
controls the timing and targeting of important biological
processes such as DNA replication, methyl-directed mis-
match repair, and transposition [37]. In addition, adenine
methylation regulates the expression of at least 20 genes
known to be induced during infection by Salmonella [38].
The suppression of gene expression in eukaryotes has been
found to be related to the presence of a variety of methylated
bases, especially 5-methylcytosine and N6-methyladenine.
Treatment with benzyladenine as a hypomethylating base
analog decreased the level of adenine methylation in a plant.
This was accompanied by a restoration of transcriptionalactivity in photosynthetic genes that are usually suppressed
[39]. Although there has been no report that adenine meth-
ylation is associated with the differentiation of leukemia
cells, several reports have proposed that DNA methylation at
cytosine residues is closely associated with the suppression
of differentiation and that demethylating agents can induce
the differentiation of leukemia cells [40–42]. These results
suggest that the manipulation of adenine methylation by
cytokinins might be, at least partly, involved in the induction
of differentiation of myelomonocytic leukemia cells. In the
present study, however, most of the labels incorporated into
DNA and RNAwere adenine nucleotides, not benzyladenine
nucleotides, suggesting that the modification of DNA/RNA
by cytokinins is minimal in human myeloid leukemia cells,
even when they are incubated with high concentrations of
cytokinins.
Extracellular ATP and other nucleotides have been iden-
tified as important signaling molecules that mediate diverse
biological effects via cell surface receptors called purinergic
receptors, or P2 receptors. The differentiation-inducing ac-
tivity of cytokinins is closely associated with the synthesis of
their nucleotides in HL-60 cells, and the cells express several
types of purinergic receptors. The expression of P2 receptors
has been shown to be affected during the granulocytic and
monocytic differentiation of HL-60 cells; some receptors
showed up-regulation, while others showed no change or
down-regulation [43,44]. Extracellular ATP suppressed the
growth of HL-60 cells and induced their differentiation [19].
ATP-induced differentiation was suggested to involve the
activation of cell surface P2 receptors coupled to cAMP
generation and the activation of protein kinase A [19].
However, the present data indicate that cytokinins suppress
the growth of HL-60 cells and induce their differentiation by
a mechanism distinct from that of extracellular ATP. The
differentiation-inducing activity of ATP was very modest,
while cytokinins were potent at inducing the differentiation
of HL-60 cells. The addition of ATP or AMP only had
additive effects on cytokinin-induced differentiation, i.e.,
neither synergism nor interference. Cytokinins did not affect
cAMP generation (data not shown), and several inhibitors of
adenyl cyclase and protein kinase A also did not essentially
affect cytokinin-induced differentiation (Table 2). Moreover,
some P2 receptor antagonists also did not affect differenti-
ation and benzyladenine nucleotides were not released from
cells into the medium in intact form. These results suggest
that cytokinin-induced differentiation is not associated with
signal transduction mediated by P2 receptors. Several antag-
onists of adenosine receptors also did not affect cytokinin-
induced differentiation.
8-CPT-cAMP and 2V,5V-dideoxyAdo significantly inhibited
IPA-induced NBT reduction by HL-60 cells. These inhibi-
tory effects were confirmed by measuring other differentia-
tion-associated phenotypes as well as by a morphological
examination. Both compounds also reversed the growth
inhibition by IPA. 8-CPT-cAMP might be a competitive
antagonist for IPA, and the inhibitory effect of 2V,5V-dideox-
Y. Ishii et al. / Biochimica et Biophysica Acta 1643 (2003) 11–24 23yAdo was prominent in the presence of Ado, suggesting that
these drugs act at the same or very close sites to induce the
differentiation of HL-60 cells.
Benzyladenine nucleotide monophosphate is the major
product in benzyladenine-treated HL-60 cells, suggesting
that adenine phosphoribosyltransferase can use benzylade-
nine as a substrate. However, the monophosphate might be
scarcely metabolized by enzymes that catalyze the phos-
phorylation of AMP. Although the role of the MAPK
pathway in the induction of differentiation of HL-60 leuke-
mia cells is not entirely clear, phosphorylation and activa-
tion of MAPK has been reported to occur after the addition
of ATRA [21]. Both adenine- and urea-cytokinins activated
MAPK in HL-60 cells before inducing granulocytic differ-
entiation and cell cycle arrest. MAPK activation by MAPK
kinase (MEK) was necessary for cytokinin-induced differ-
entiation in studies using PD98059 to block MEK phos-
phorylation. Several inhibitors against the other signal
transduction pathways did not affect IPA-induced differen-
tiation. These results suggest that both adenine- and urea-
cytokinins induce differentiation of leukemia cells primarily
through activation of MAPK, although we cannot eliminate
the possible involvement of other signal transduction path-
ways. Further experimentation is necessary to understand
the significance of MAPK activation in the cytokinin-
induced differentiation of leukemia cells.Acknowledgements
This work was supported in part by Grants for Cancer
Research from the Ministry of Education, Culture, Sports,
Science and Technology, and the Ministry of Health, Welfare
and Labor, Japan.References
[1] M. Hozumi, Fundamentals of chemotherapy of myeloid leukemia by
induction of leukemia cell differentiation, Adv. Cancer Res. 38 (1983)
121–169.
[2] H.P. Koeffler, Induction of differentiation of human acute myelog-
enous leukemia cells: therapeutic implications, Blood 62 (1983)
709–721.
[3] M. Leszczyniecka, T. Roberts, P. Dent, S. Grant, P.B. Fisher, Differ-
entiation therapy of human cancer: basic science and clinical appli-
cations, Pharmacol. Ther. 90 (2001) 105–156.
[4] Y. Honma, Cotylenin A-a plant growth regulator as a differentiation-
inducing agent against myeloid leukemia, Leuk. Lymphoma 43
(2002) 169–1178.
[5] C.M. Chen, Cytokinin biosynthesis and interconversion, Physiol.
Plant. 101 (1997) 665–673.
[6] C.O. Miller, F. Skoog, M.H. Von Saltza, M. Strong, Kinetin, a cell
division factor from deoxyribonucleic acid, J. Am. Chem. Soc. 77
(1955) 1329–1334.
[7] M.C. Mok, in: D.W.S. Mok, M.C. Mok (Eds.), Cytokinins and Plant
Development—An Overview. Cytokinins—Chemistry, Activity and
Function, CRC Press, Boca Ranton, FL, 1994, pp. 155–166.
[8] G. Shaw, in: D.W.S. Mok, M.C. Mok (Eds.), Chemistry of AdenineCytokinins. Cytokinins—Chemistry, Activity and Function, CRC
Press, Boca Ranton, FL, 1994, pp. 15–34.
[9] Y. Ishii, Y. Hori, S. Sakai, Y. Honma, Control of differentiation and
apoptosis of human myeloid leukemia cells by cytokinins and cyto-
kinin nucleosides, plant redifferentiation-inducing hormones, Cell
Growth Differ. 13 (2002) 19–26.
[10] S.J. Collins, R.C. Gallo, R.E. Gallagher, Continuous growth and dif-
ferentiation of human myeloid leukaemic cells in suspension culture,
Nature 270 (1977) 347–349.
[11] M. Camici, M. Turriani, M.G. Tozzi, G. Turchi, J. Cos, C. Alemany,
A. Miralles, V. Noe, C. Ciudad, Purine enzyme profile in human
colon-carcinoma cell lines and differential sensitivity to deoxycofor-
mycin and 2V-deoxyadenosine in combination, Int. J. Cancer 62 (1995)
176–183.
[12] M. Makishima, Y. Honma, M. Hozumi, K. Sampi, M. Hattori, I. Ishi-
kawa, H. Ogura, N. Kawahara, T. Kanaiwa, K.Motoyoshi, Induction of
differentiation of human myeloid leukemia HL-60 cells by novel pyr-
imidine nucleoside analogs, Biochim. Biophys. Acta 1094 (1991) 1–7.
[13] Y. Honma, J. Okabe-Kado, M. Hozumi, Y. Uehara, S. Mizuno, In-
duction of erythroid differentiation of K562 human leukemic cells by
herbimycin A, an inhibitor of tyrosine kinase activity, Cancer Res. 49
(1989) 331–334.
[14] P. Chomczynski, A reagent for the single-step simultaneous isolation
of RNA, DNA and proteins from cell and tissue samples, BioTechni-
ques 15 (1993) 532–534.
[15] A.F. Brumm, V.R. Potter, P. Siekevitz, Nucleotide metabolism V.
Incorporation of P32 into acid-soluble nucleotides of rat liver in vivo,
J. Biol. Chem. 22 (1956) 713–722.
[16] C.B. Lozzio, B.B. Lozzio, E.A. Machado, J.E. Fuhr, S.U. Lair, E.G.
Bamberger, Effects of sodium butyrate on human chronic meyloge-
nous leukaemia cell line K562, Nature 281 (1979) 709–710.
[17] G. Tortora, H. Yokozaki, S. Pepe, T. Clair, Y.S. Cho-Chung, Differ-
entiation of HL-60 leukemia by type 1 regulatory subunit antisense
oligodeoxynucleotide of cAMP-dependent protein kinase, Proc. Natl.
Acad. Sci. U. S. A. 88 (1991) 2011–2015.
[18] A.D. Conigrave, L. van der Weyden, L. Holt, L. Jiang, P. Wilson, R.I.
Christopherson, M.B. Morris, Extracellular ATP-dependent suppres-
sion of proliferation and induction of differentiation of human HL-60
leukemia cells by distinct mechanisms, Biochem. Pharmacol. 60
(2000) 1585–1591.
[19] U. Schulze-Gahmen, J. Brandsen, H.D. Jones, D.O.Morgan, L.Meijer,
J. Versely, S.-H. Kim, Multiple modes of ligand recognition: crystal
structures of cyclin-dependent protein kinase 2 in complex with ATP
and two inhibitors, olomoucine and isopentenyladenine, Proteins 22
(1995) 378–391.
[20] S. Trumpp-Kallmeyer, J.R. Rubin, C. Humblet, J.M. Hamby, H.D.
Showalter, Development of a binding model to protein tyrosine kinase
for substituted pyrido[2,3-d]pyridine inhibitors, J. Med. Chem. 41
(1998) 1752–1763.
[21] A. Yen, M.S. Roberson, S. Varvayanis, A.T. Lee, Retinoic acid in-
duced mitogen-activated protein (MAP)/extracellular signal-regulated
kinase (ERK) kinase-dependent MAP kinase activation needed to
elicit HL-60 cell differentiation and growth arrest, Cancer Res. 58
(1998) 3163–3172.
[22] O.N. Kulaeva, T.K. Zagranichnaya, F.A. Brovko, N.N. Karavaiko,
Y.S. Selivankina, Y.V. Zemlyachenko, M. Hall, V.M. Lipkin, K.M.
Boziev, A new family of cytokinin receptors from Cereales, FEBS
Lett. 423 (1998) 239–242.
[23] M. Brault, O. Caiveau, J. Pendron, R. Maldiney, B. Sotta, E. Migi-
niac, Detection of membrane-bound cytokinin-binding proteins in
Arabidopsis thaliana cells, Eur. J. Biochem. 260 (1999) 512–519.
[24] T. Inoue, M. Higuchi, Y. Hashimoto, M. Seki, M. Kobayashi, T. Kato,
S. Tabata, K. Shinozaki, T. Kakimoto, Identification of CRE1 as a
cytokinin receptor from Arabidopsis, Nature 409 (2001) 1060–1063.
[25] C. Ueguchi, S. Sato, T. Kato, S. Tabata, The AHK4 gene involved in
the cytokinin-signaling pathway as a direct receptor molecule in Ara-
bidopsis thaliana, Plant Cell Physiol. 42 (2001) 751–755.
Y. Ishii et al. / Biochimica et Biophysica Acta 1643 (2003) 11–2424[26] B. Gillissen, L. Burkle, B. Andre, C. Kuhn, D. Rentsch, B. Brandl,
W.B. Frommer, A new family of high-affinity transporters for adenine,
cytosine, and purine derivatives in Arabidopsis, Plant Cell 12 (2000)
291–300.
[27] D.J. Armstrong, N. Murai, B.J. Taller, F. Skoog, Incorporation of
cytokinin N6-benzyladenine into tobacco callus transfer ribonucleic
acid and ribosomal ribonucleic acid preparations, Plant Physiol. 57
(1976) 15–22.
[28] N. Murai, B.J. Taller, D.J. Armstrong, F. Skoog, Kinetin incorporated
into tobacco callus ribosomal RNA and transfer RNA preparations,
Plant Physiol. 60 (1977) 197–202.
[29] J. Jouanneau, B. Teyssendier de la Serve, C. Peaud-Lenoel, Fre-
quency of N6-benzyladenine incorporation into major RNA reactions
of tobacco cell suspensions grown at stimulatory or cytostatic cyto-
kinin concentration, Plant Physiol. 74 (1984) 663–668.
[30] B. Teyssendier de la Serve, J. Jouanneau, C. Peaud-Lenoel, Incorpo-
ration of N6-benzyladenine into messenger poly(A)-RNA of tobacco
cells incubated at stimulatory or cytostatic cytokinin concentration,
Plant Physiol. 74 (1984) 669–674.
[31] B.J. Taller, N. Murai, F. Skoog, Endogenous cytokinins in the ribo-
somal RNA of higher plants, Plant Physiol. 83 (1987) 755–760.
[32] M. Buck, E. Griffiths, Regulation of aromatic amino acid transport by
tRNA: role of 2-methylthio-N6-(D2-isopentenyl)-adenosine, Nucleic
Acids Res. 9 (1981) 401–414.
[33] M. Buck, B.N. Ames, A modified nucleotide in tRNA as a possible
regulator of aerobiosis: synthesis of cis-2-methylthioribosylzeatin in
the tRNA of Salmonella, Cell 36 (1984) 523–531.
[34] G.J. Warner, C.P. Rusconi, I.E. White, J.R. Faust, Identification and
sequencing of two isopentenyladenosine-modified transfer RNAs
from Chinese hamster ovary cells, Nucleic Acids Res. 26 (1998)
5533–5535.
[35] K.A. Kretz, J.R. Katze, R.W. Trewyn, Guanine analog-induced differ-
entiation of human promyelocytic leukemia cells and changes in
queuine modification of tRNA, Mol. Cell. Biol. 7 (1987) 3613–3619.
[36] B.T. French, D.E. Patrick, M.R. Grever, R.W. Trewyn, Queuine, atRNA anticodon wobble base, maintains the proliferative and pluripo-
tent potential of HL-60 cells in the presence of the differentiating agent
6-thioguanine, Proc. Natl. Acad. Sci. U. S. A. 88 (1991) 370–374.
[37] M. van der Woude, B. Braaten, D. Low, Epigenentic phase variation of
the pap operon in Escherichia coli, Trends Microbiol. 4 (1996) 5–9.
[38] D.M. Heithoff, R.L. Sinsheimer, D.A. Low, M.J. Mahan, An essential
role for DNA adenine methylation in bacterial virulence, Science 284
(1999) 967–970.
[39] J. Ngernprasirtsiri, T. Akazawa, Modulation of DNA methylation and
gene expression in cultured sycamore cells treated by hypomethylat-
ing base analog, Eur. J. Biochem. 194 (1990) 513–520.
[40] R.L. Momparler, J. Bouchard, J. Samson, Induction of differentiation
and inhibition of DNA methylation in HL-60 myeloid leukemic cells
by 5-AZA-2V-deoxycytidine, Leuk. Res. 9 (1985) 1361–1366.
[41] Pinto, V. Attadia, A. Fusco, F. Ferrara, O.A. Spada, P.P. Di Fiore, 5-
Aza-2V-deoxycytidine induces terminal differentiation of leukemic
blasts from patients with acute myeloid leukemias, Blood 64 (1984)
922–929.
[42] N. Niitsu, Y. Hayashi, K. Sugita, Y. Honma, Sensitization by 5-aza-2V-
deoxycytidine of leukaemia cells with MLL abnormalities to induc-
tion of differentiation by all-trans retinoic acid and 1a,25-dihydrox-
yvitamin D3, Br. J. Haematol. 112 (2001) 315–326.
[43] G. Buell, A.D. Michel, C. Lewis, G. Collo, P.P.A. Humphrey, A.
Surprenant, P2X1 receptor activation in HL60 cells, Blood 87
(1996) 2659–2664.
[44] K. Adrian, M.K. Bernhard, H. Breitinger, A. Ogilvie, Expression of
purinergic receptors (ionotropic P2X1-7 and metabotropic P2Y1-11)
during myeloid differentiation of HL60 cells, Biochim. Biophys. Acta
1492 (2000) 127–138.
[45] M.C. Berenbaum, What is synergy? Pharmacol. Rev. 41 (1989)
93–141.
[46] M. Makishima, J. Okabe-Kado, Y. Honma, Growth inhibition and
differentiation induction in human monoblastic leukaemia cells by
1a-hydroxyvitamin D derivatives and their enhancement by combi-
nation with hydroxyurea, Br. J. Cancer 77 (1998) 33–39.
